Literature DB >> 1483482

Large intercommunity difference in cardiovascular drug consumption: relation to mortality, risk factors and socioeconomic differences.

M Oreberg1, G G Jonsson, K West, M Eberhard-Grahn, L Råstam, A Melander.   

Abstract

A comparison of cardiovascular drug sales and cardiovascular mortality was made between two Swedish counties (Värmland and Malmöhus) and between two rural municipalities in those counties (Torsby in Värmland and Hörby in Malmöhus). Cardiovascular drug sales (defined daily doses (DDD) per 1,000 inhabitants per day) during 1986-87 were 25% higher in Värmland than in Malmöhus county, and the age-standardized mortality of coronary heart disease (CHD) was 36% (men) and 54% (women) higher. In Torsby, age-standardized CHD mortality (1986-87) was 71% (both sexes) higher than in Hörby, and the sales of cardiovascular drugs (1978-87) were 58% higher. Statistically, every third inhabitant of Torsby took one DDD of a cardiovascular drug every day, as compared to every fifth inhabitant in Hörby. In Torsby there was a 6% higher serum cholesterol, 71% lower tap water hardness, 33% lower income, a lower educational level, a three-fold higher unemployment rate, and a different ethnic background (20% eastern Finnish ancestry), all factors assumed to promote a high CHD rate. All of these factors may contribute to the higher CHD mortality, which was in turn reflected in higher sales of cardiovascular drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1483482     DOI: 10.1007/bf02285084

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  EFFECTS OF ORAL CALCIUM UPON SERUM LIPIDS IN MAN.

Authors:  H YACOWITZ; A I FLEISCHMAN; M L BIERENBAUM
Journal:  Br Med J       Date:  1965-05-22

2.  Measurement of drug use in a defined population. Evaluation of the defined daily dose (DDD) methodology.

Authors:  A Wessling; G Boëthius
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  On the differences in psychotropic drug use between the three major urban areas in Sweden.

Authors:  A Wessling; U Bergman; B Westerholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Cholesterol and coronary heart disease. A new era.

Authors:  S M Grundy
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

5.  Anxiolytic-hypnotic drugs: relationships between prescribing, abuse and suicide.

Authors:  A Melander; K Henricson; P Stenberg; P Löwenhielm; J Malmvik; B Sternebring; L Kaij; U Bergdahl
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Utilization of antidiabetic drugs in the Island of Gotland, Sweden: agreement between wholesale figures and prescription data.

Authors:  U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

7.  The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden.

Authors:  U Bergman; P Elmes; M Halse; T Halvorsen; H Hood; P K Lunde; F Sjöqvist; O L Wade; B Westerholm
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

8.  Effects of dietary calcium upon lipid metabolism in mature male rats fed beef tallow.

Authors:  A I Fleischman; H Yacowitz; T Hayton; M L Bierenbaum
Journal:  J Nutr       Date:  1966-03       Impact factor: 4.798

9.  Risk factors for ischaemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm Prospective Study.

Authors:  L A Carlson; L E Böttiger
Journal:  Acta Med Scand       Date:  1985

10.  Alcohol and cardiovascular disease: the status of the U shaped curve.

Authors:  M Marmot; E Brunner
Journal:  BMJ       Date:  1991-09-07
View more
  1 in total

1.  Age standardisation of drug utilisation: comparisons of different methods using cardiovascular drug data from Sweden and Spain.

Authors:  J Merlo; J Ranstam; L Råstam; A Wessling; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.